News
CHMP Endorses Attrogy for Amyloidosis
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Attrogy , intended for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
The benefits of Attrogy are its ability to delay disease progression, measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7), at 2 years of treatment versus placebo, as shown in a randomised, double-blind, placebo-controlled clinical trial. The most common side effects are gastro-intestinal.
Condition: ATTR (hATTR) amyloidosis + Polyneuropathy
Type: drug